Biosimilars: What HR Leaders Need to Know in 5 Minutes

A plain-English brief for HR and consultants: coverage trends, new launches, simpler FDA rules, and a member-first playbook to lower net cost—without disrupting care.

  • 2 Min read

  • November 24, 2025

Susan Thomas

Susan Thomas

Chief Commercial Officer, LucyRx
Best Practices
woman looking at her perception

If we had five minutes between meetings, here’s what I’d share: biosimilars are no longer a maybe. They’re a practical way to protect your budget and keep care steady for your people.

What this means for your people: You can lower specialty spend without disrupting care. In 2024, biosimilars contributed $20.2B in U.S. savings.3

Why now

  • Coverage is moving your way. Payers are preferring biosimilars with formulary placement, member-friendly copays, and aligned provider incentives.
  • Rules got simpler. FDA draft guidance says most switching studies aren’t needed to earn “interchangeable.”1 The FDA also confirms biosimilars and interchangeables meet the same safety and effectiveness standard.2
  • New launches expanded the opportunity. Autoimmune, bone health, and eye-care categories now have biosimilars, many priced far below the brand. That creates room to lower net spend without disrupting care.

What this means for employers

Momentum only turns into value when your plan prefers lowest net cost and the lower-cost therapy is the easy default for your people. That takes clear design, thoughtful communications, and hands-on support—so employees feel cared for and stay on therapy without friction.

What our data shows

When we pair analytics with hands-on support, utilization moves to lowest net cost—without disrupting care.

In inflammatory conditions, we’ve modeled a shift from Humira® >40% (even after exclusion) to <10%, next-gen brands down to ~10%, and biosimilars up to 85%+—moving projected cost from $23 → $12 PMPM and clarifying $11 PMPM net savings. (Modeled results; your plan’s results will vary.)

Make the right choice the easy choice

  • Design for net value: Prefer the lowest-net-cost option (not the highest rebate)
  • Enable substitution where allowed. Interchangeability permits pharmacist substitution (subject to state law; requirements vary).2 Set a simple policy and explain it in plain language.
  • Support people through change: Offer device training, refill sync, and a clear support line so the experience feels personal and steady.
  • Measure what matters: Track adoption %, PMPM, employee out-of-pocket, provider patterns, and appeal rates—quarter by quarter.

The takeaway

Coverage decisions start the story; engagement finishes it. With the right guardrails and care, employers can reduce specialty spend and protect the member experience.

Ask us for a 30-minute biosimilar opportunity review for your plan.

Put LucyRx Care Guides to work for your people—and your retention.

Contact Us
Sources
[1] FDA Draft Guidance: Considerations for Demonstrating Interchangeability… (June 20, 2024).
U.S. Food and Drug Administration
[2] FDA: 9 Things to Know About Biosimilars and Interchangeable Biosimilars (consumer explainer).
U.S. Food and Drug Administration
[3] Association for Accessible Medicines/IQVIA: 2025 U.S. Generic & Biosimilar Medicines Savings Report (biosimilar savings: $20.2B in 2024; $56.2B since 2015).
Association for Accessible Medicines

Tags

Biosimilars

Recommended Reads

doctor writing a prescription

PBM Reform Update: What the CAA and DOL Proposal Mean for Plan Sponsors

With the Consolidated Appropriations Act of 2026 and a Department of Labor proposal focused on PBM disclosures, employers are seeing more headlines and asking sharper questions about how their pharmacy benefits are structured.
woman and doctor

Making Menopause Support Real: What Employers Are Asking and How We Help

Menopause affects retention, productivity, and healthcare costs. Learn why employers are making menopause support a core benefits strategy.
woman talking

Menopause Is a Workforce Issue. Your Pharmacy Benefit Should Treat It That Way.

Menopause affects productivity, retention, and healthcare costs. Learn why pharmacy benefit design is central to effective menopause support.
Menopause benefits

Menopause Benefits: From Nice-to-Have to Business Imperative

Menopause affects retention, productivity, and healthcare costs. Learn why employers are making menopause support a core benefits strategy.
Woman and Pharmacist

Why “Affordability” Became the Word of the Moment — and What Healthcare Misses

Healthcare affordability is not just about price. Learn what patients experience at the pharmacy counter and why unpredictability erodes trust.
Connected Specialty Care Network + Care Guides

The Difference Between Access on Paper and Access in Practice

Understand why specialty drug access breaks down after coverage is approved and how employers can close the gap between coverage and care.
Woman receiving a prescription

Behind Every Claim Is a Person: Why Prescription Care Needs a Different Playbook in 2026

If you spend your days looking at pharmacy trend reports and renewal spreadsheets, it is easy to forget what those numbers really represent.
employees talking to each other

The Hidden Driver of Employee Experience (and Retention): Human-Led Care Guides

Human-led Care Guides reduce friction in complex medication moments, helping employees start and stay on therapy. The result: better experience, higher confidence, and stronger retention for employers.
doctor and patient

The Yardstick That Matters: Redefining Outcomes in Prescription Care

Outcomes don’t improve by accident. Better processes, faster therapy access, and clear guidance are the foundation of patient-centered prescription care—and the new standard employers should expect.
formulary design that captures savings

Formulary design that captures the savings (without disruption)

Rebates don’t equal value. Here’s how to align to net cost, enable substitution, and keep your people on track.
PreviousNext
doctor writing a prescription

PBM Reform Update: What the CAA and DOL Proposal Mean for Plan Sponsors

With the Consolidated Appropriations Act of 2026 and a Department of Labor proposal focused on PBM disclosures, employers are seeing more headlines and asking sharper questions about how their pharmacy benefits are structured.
woman and doctor

Making Menopause Support Real: What Employers Are Asking and How We Help

Menopause affects retention, productivity, and healthcare costs. Learn why employers are making menopause support a core benefits strategy.
woman talking

Menopause Is a Workforce Issue. Your Pharmacy Benefit Should Treat It That Way.

Menopause affects productivity, retention, and healthcare costs. Learn why pharmacy benefit design is central to effective menopause support.
Menopause benefits

Menopause Benefits: From Nice-to-Have to Business Imperative

Menopause affects retention, productivity, and healthcare costs. Learn why employers are making menopause support a core benefits strategy.
Woman and Pharmacist

Why “Affordability” Became the Word of the Moment — and What Healthcare Misses

Healthcare affordability is not just about price. Learn what patients experience at the pharmacy counter and why unpredictability erodes trust.
Connected Specialty Care Network + Care Guides

The Difference Between Access on Paper and Access in Practice

Understand why specialty drug access breaks down after coverage is approved and how employers can close the gap between coverage and care.
Woman receiving a prescription

Behind Every Claim Is a Person: Why Prescription Care Needs a Different Playbook in 2026

If you spend your days looking at pharmacy trend reports and renewal spreadsheets, it is easy to forget what those numbers really represent.
employees talking to each other

The Hidden Driver of Employee Experience (and Retention): Human-Led Care Guides

Human-led Care Guides reduce friction in complex medication moments, helping employees start and stay on therapy. The result: better experience, higher confidence, and stronger retention for employers.
doctor and patient

The Yardstick That Matters: Redefining Outcomes in Prescription Care

Outcomes don’t improve by accident. Better processes, faster therapy access, and clear guidance are the foundation of patient-centered prescription care—and the new standard employers should expect.
PreviousNext

LucyRx is a fast-scaling, independent, next-generation pharmacy benefit manager (PBM) redefining prescription care for plan sponsors and members nationwide.

Follow us

Linkedin Linkedin Tiktok Tiktok Instagram Instagram

Copyright © 2026 by LucyRx. All Rights Reserved | Privacy Policy | Terms of Use | Members Rights

PBM Reform Readiness Checklist for EmployersPBM Reform Readiness Checklist for EmployersCFO Case for Care GuidesThe CFO Case for Care Guides: From Cost Pressure to Controllable Results

Download the PBM Reform Readiness Checklist

Download the GLP-1 Planning Checklist